Literature DB >> 33668097

Collagen Type XI Alpha 1 (COL11A1): A Novel Biomarker and a Key Player in Cancer.

Sameera Nallanthighal1, James Patrick Heiserman1, Dong-Joo Cheon1.   

Abstract

Collagen type XI alpha 1 (COL11A1), one of the three alpha chains of type XI collagen, is crucial for bone development and collagen fiber assembly. Interestingly, COL11A1 expression is increased in several cancers and high levels of COL11A1 are often associated with poor survival, chemoresistance, and recurrence. This review will discuss the recent discoveries in the biological functions of COL11A1 in cancer. COL11A1 is predominantly expressed and secreted by a subset of cancer-associated fibroblasts, modulating tumor-stroma interaction and mechanical properties of extracellular matrix. COL11A1 also promotes cancer cell migration, metastasis, and therapy resistance by activating pro-survival pathways and modulating tumor metabolic phenotype. Several inhibitors that are currently being tested in clinical trials for cancer or used in clinic for other diseases, can be potentially used to target COL11A1 signaling. Collectively, this review underscores the role of COL11A1 as a promising biomarker and a key player in cancer.

Entities:  

Keywords:  COL11A1; biomarker; cancer-associated fibroblasts; chemoresistance; collagen; metastasis

Year:  2021        PMID: 33668097     DOI: 10.3390/cancers13050935

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  10 in total

1.  SPP1 facilitates cell migration and invasion by targeting COL11A1 in lung adenocarcinoma.

Authors:  Xuan Yi; Linlin Luo; Yanzhen Zhu; Hong Deng; Huitian Liao; Yang Shen; Yan Zheng
Journal:  Cancer Cell Int       Date:  2022-10-20       Impact factor: 6.429

Review 2.  The Functional Role of Extracellular Matrix Proteins in Cancer.

Authors:  Nadezhda V Popova; Manfred Jücker
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

3.  Matrix Effectors and Cancer.

Authors:  Zoi Piperigkou; Nikos K Karamanos
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

4.  Development and Validation of a Six-Gene Prognostic Signature for Bladder Cancer.

Authors:  Fei Xu; Qianqian Tang; Yejinpeng Wang; Gang Wang; Kaiyu Qian; Lingao Ju; Yu Xiao
Journal:  Front Genet       Date:  2021-12-06       Impact factor: 4.599

Review 5.  Collagen XI Alpha 1 Chain, a Novel Therapeutic Target for Cancer Treatment.

Authors:  Yi-Hui Wu; Cheng-Yang Chou
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

6.  LINC00665/miRNAs axis-mediated collagen type XI alpha 1 correlates with immune infiltration and malignant phenotypes in lung adenocarcinoma.

Authors:  Jun Zhu; Yuan Weng; Fudong Wang; Jun Zhao
Journal:  Open Med (Wars)       Date:  2022-07-13

7.  Searching for the methylation sites involved in human papillomavirus type 16 and 18‑positive women with cervical cancer.

Authors:  Yanyun Ma; Chunxia Wang; Mengqi Shi; Mingshan Li; Lin Li; Tuanjie Che; Jing Qu
Journal:  Mol Clin Oncol       Date:  2022-09-02

8.  COL11A1 as a potential prognostic target for oral squamous cell carcinoma.

Authors:  Yong-Bin Di; Yang Bao; Jie Guo; Wei Liu; Su-Xin Zhang; Guan-Hua Zhang; Tian-Ke Li
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

Review 9.  Decellularized Colorectal Cancer Matrices as Bioactive Scaffolds for Studying Tumor-Stroma Interactions.

Authors:  Ângela Marques-Magalhães; Tânia Cruz; Ângela Margarida Costa; Diogo Estêvão; Elisabete Rios; Pedro Amoroso Canão; Sérgia Velho; Fátima Carneiro; Maria José Oliveira; Ana Patrícia Cardoso
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

10.  miR-335 Restrains the Aggressive Phenotypes of Ovarian Cancer Cells by Inhibiting COL11A1.

Authors:  Yi-Hui Wu; Yu-Fang Huang; Tzu-Hao Chang; Pei-Ying Wu; Tsung-Ying Hsieh; Sheng-Yen Hsiao; Soon-Cen Huang; Cheng-Yang Chou
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.